The FDA has approved Zepbound (tirzepatide) for adults with obstructive sleep apnea and obesity, showing significant efficacy in treating the condition. Results from the SURMOUNT-OSA phase 3 clinical trials demonstrated that Zepbound was more effective than a placebo, leading to weight loss and improvement in OSA symptoms. Participants using Zepbound alone or in combination with positive airway pressure therapy experienced remission or mild symptoms of OSA. The drug was also associated with substantial weight loss in participants. This approval marks a significant advancement in the treatment of OSA and its related health issues, providing a new option for patients.
Source link
FDA approves Zepbound for moderate to severe OSA, obesity
